… fluoroquinolone monotherapy and β-lactam with or without macrolide for non-ICU hospitalized
CAP patients… the comparison of respiratory fluoroquinolone monotherapy and β-lactam …

… Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality. This
review compared two of the main treatment alternatives: quinolone or macrolide monotherapy …

… majority of the trials that compared fluoroquinolones with monotherapy. Patients with
bacteremic pneumonia did not seem to benefit more from fluoroquinolones than from β-lactams or …

… or monotherapy with a respiratory fluoroquinolone should be considered equivalent in
this latter patient … in all patients with mild-to-moderate CAP seems unnecessary, and β-lactam …

… -analysis comparing respiratory fluoroquinolone monotherapy to ceftriaxone combination
therapy for community-acquired pneumonia has been published. A total of 1520 patients in 9 …

… Hence, it should be noted that no study had evaluated outcomes following β-lactam-macrolide
combination therapy versus fluoroquinolone monotherapy for PSI class V VA patients …

… , and discusses new trends in pneumonia epidemiology and outcomes … fluoroquinolone
monotherapy is associated with improved patient survival compared with β-lactam monotherapy …

… For hospitalized patients, monotherapy with a respiratory fluoroquinolone agent seems to
be gaining popularity, but dual therapy combining a β-lactam and an advanced macrolide still …

… or doxycycline or monotherapy with a “respiratory quinolone” (ie, a fluoroquinolone with
a high … established recommendations for patients with community-acquired pneumonia (CAP) …

… improved outcomes with monotherapy makes it difficult to recommend the use of a β-lactam
with a macrolide over that of monotherapy with a respiratory fluoroquinolone. Although many …